[go: up one dir, main page]

GT200800273A - Polipeptidos de factor de crecimiento de tipo insulina estabilizada - Google Patents

Polipeptidos de factor de crecimiento de tipo insulina estabilizada

Info

Publication number
GT200800273A
GT200800273A GT200800273A GT200800273A GT200800273A GT 200800273 A GT200800273 A GT 200800273A GT 200800273 A GT200800273 A GT 200800273A GT 200800273 A GT200800273 A GT 200800273A GT 200800273 A GT200800273 A GT 200800273A
Authority
GT
Guatemala
Prior art keywords
growth factor
type growth
factor polypeptides
insulin type
stabilized insulin
Prior art date
Application number
GT200800273A
Other languages
English (en)
Inventor
Glass David Jonathan
Fornaro Mara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800273(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800273A publication Critical patent/GT200800273A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A POLIPEPTIDOS ESTABILIZADOS QUE TIENEN UNA SECUENCIA DE IGF-1 Ó IGF-2 Y UNA SECUENCIA DE PEPTIDO E, EN DONDE LA ESCISION FISIOLOGICA NATURAL DEL PEPTIDO E A PARTIR DE IGF ES EVITADA. T2008
GT200800273A 2006-06-09 2008-12-04 Polipeptidos de factor de crecimiento de tipo insulina estabilizada GT200800273A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24

Publications (1)

Publication Number Publication Date
GT200800273A true GT200800273A (es) 2009-09-16

Family

ID=38801859

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800273A GT200800273A (es) 2006-06-09 2008-12-04 Polipeptidos de factor de crecimiento de tipo insulina estabilizada

Country Status (33)

Country Link
US (4) US8343918B2 (es)
EP (2) EP2032154A2 (es)
JP (2) JP5290966B2 (es)
KR (1) KR101459789B1 (es)
AR (1) AR061242A1 (es)
AU (2) AU2007257936B2 (es)
BR (2) BRPI0712052A2 (es)
CA (2) CA2653781A1 (es)
CL (1) CL2007001614A1 (es)
CR (2) CR10432A (es)
CY (1) CY1116117T1 (es)
DK (2) DK2032155T3 (es)
EC (1) ECSP088949A (es)
ES (1) ES2529261T3 (es)
GT (1) GT200800273A (es)
HK (1) HK1126429A1 (es)
HR (1) HRP20150326T1 (es)
IL (1) IL195156A (es)
JO (1) JO2968B1 (es)
MA (1) MA30503B1 (es)
MX (2) MX2008015657A (es)
MY (1) MY147856A (es)
NO (2) NO20085184L (es)
NZ (2) NZ572708A (es)
PE (1) PE20080715A1 (es)
PL (1) PL2032155T3 (es)
PT (1) PT2032155E (es)
RU (1) RU2477287C2 (es)
SI (1) SI2032155T1 (es)
TN (1) TNSN08509A1 (es)
TW (1) TWI427084B (es)
UA (1) UA97953C2 (es)
WO (2) WO2007146689A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
EP2032154A2 (en) 2006-06-09 2009-03-11 Novartis Ag Stabilized insulin-like growth factor polypeptides
EP3272773B8 (en) * 2008-05-07 2020-11-18 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
BRPI0921261A2 (pt) * 2008-11-10 2018-10-23 Novartis Ag anticorpos que se ligam imunoespecificamente a peptídeos igf-1 humanos modificados , hibridoma, polipeptídeo isolado, ácido nucleico que codifica um anticorpo, vetor compreendendo um ácido nucléico, célula hospedeira compreendendo um vetor, ensaio imunosorvente ligado a enzima aperfeiçoado (elisa), método de manter uma dose ótima de igf-1/e modificada, método cromatográfico de afinidade aperfeiçoado e uso de igf-1/e modificado.
US8685403B2 (en) * 2009-01-30 2014-04-01 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
CN102753578B (zh) 2009-04-27 2015-04-22 诺华股份有限公司 增加肌肉生长的组合物和方法
CN102510757B (zh) 2009-07-22 2015-03-18 益普生制药股份有限公司 在第59位置处具有氨基酸替换的胰岛素样生长因子-1(igf-1)类似物
DK2498796T3 (en) * 2009-11-09 2018-03-05 Aal Scient Inc HEART DISEASE TREATMENT
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
CA2827187C (en) 2011-02-23 2019-01-08 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012178146A1 (en) * 2011-06-24 2012-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of spinal muscular atrophy
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
JP6392245B2 (ja) * 2012-12-18 2018-09-19 ノバルティス アーゲー 遺伝子改変哺乳動物細胞における治療用タンパク質の産生
CU24308B1 (es) * 2012-12-18 2018-01-10 Novartis Ag Polipéptidos estabilizados del factor de crecimiento tipo insulina
MX2016001969A (es) 2013-08-14 2016-06-02 Novartis Ag Metodos para tratar la miositis por cuerpos de inclusion esporadica.
CA2926173A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
US10279013B2 (en) 2013-12-19 2019-05-07 Puretein Bioscience Llc Methods for treating an animal
EP3100056A2 (en) 2014-01-27 2016-12-07 Novartis AG Biomarkers predictive of muscle atrophy, method and use
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
US20180021410A1 (en) * 2015-02-04 2018-01-25 Puretein Bioscience Llc Methods for increasing performance characteristics in offspring
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
JP7005019B2 (ja) 2015-10-02 2022-02-04 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド 組織修復のための二重特異性治療用タンパク質
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
US10982000B2 (en) 2017-03-24 2021-04-20 Novartis Ag Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202342509A (zh) * 2022-01-31 2023-11-01 國立大學法人信州大學 以IGF1R為標的之pre-pro前驅體型嵌合抗原受體表現細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JPH0720993B2 (ja) 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
WO1993023067A1 (en) * 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
AU2601895A (en) 1994-05-24 1995-12-18 Amgen Boulder Inc. Modified insulin-like growth factors
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) * 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
JP3971108B2 (ja) * 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
EP2128246B1 (en) * 2001-04-19 2014-03-12 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-Aminoacyl-tRNA synthetase pairs
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
CA2503330A1 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
PL2241575T3 (pl) * 2005-01-07 2015-12-31 Regeneron Pharma Polipeptydy fuzyjne IGF-1 oraz ich zastosowania terapeutyczne
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
WO2006097764A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
JP4713579B2 (ja) 2005-03-31 2011-06-29 パイオニア株式会社 アプリケーションプログラム
EP2032154A2 (en) 2006-06-09 2009-03-11 Novartis Ag Stabilized insulin-like growth factor polypeptides

Also Published As

Publication number Publication date
CR10432A (es) 2009-01-15
BRPI0712052A2 (pt) 2012-01-10
US20130059779A1 (en) 2013-03-07
JP2009539383A (ja) 2009-11-19
ES2529261T3 (es) 2015-02-18
AU2007255419A1 (en) 2007-12-13
WO2007141309A3 (en) 2008-05-29
CA2654944A1 (en) 2007-12-21
WO2007146689A2 (en) 2007-12-21
ECSP088949A (es) 2009-01-30
US8343918B2 (en) 2013-01-01
AR061242A1 (es) 2008-08-13
US20100173839A1 (en) 2010-07-08
EP2032155A2 (en) 2009-03-11
PT2032155E (pt) 2015-04-07
CA2653781A1 (en) 2007-12-13
JP2009539805A (ja) 2009-11-19
KR101459789B1 (ko) 2014-11-07
DK200900016A (da) 2009-01-06
CL2007001614A1 (es) 2008-08-08
WO2007141309A2 (en) 2007-12-13
US8722621B2 (en) 2014-05-13
SI2032155T1 (sl) 2015-04-30
IL195156A0 (en) 2011-08-01
UA97953C2 (uk) 2012-04-10
WO2007146689A9 (en) 2010-12-16
MA30503B1 (fr) 2009-06-01
HRP20150326T1 (hr) 2015-04-24
TWI427084B (zh) 2014-02-21
RU2477287C2 (ru) 2013-03-10
CA2654944C (en) 2017-01-03
CY1116117T1 (el) 2017-02-08
BRPI0712147A2 (pt) 2012-02-22
TNSN08509A1 (en) 2010-04-14
AU2007257936A1 (en) 2007-12-21
JP5290966B2 (ja) 2013-09-18
MX2008015726A (es) 2008-12-19
NO20085184L (no) 2009-03-03
MY147856A (en) 2013-01-31
NO20085183L (no) 2009-03-09
PL2032155T3 (pl) 2015-05-29
HK1126429A1 (en) 2009-09-04
CR20160115A (es) 2016-06-14
WO2007146689A3 (en) 2008-04-10
NZ572548A (en) 2011-06-30
TW200835698A (en) 2008-09-01
EP2032155B1 (en) 2014-12-24
MX2008015657A (es) 2009-02-04
US20170066808A9 (en) 2017-03-09
AU2007257936B2 (en) 2011-05-26
EP2032154A2 (en) 2009-03-11
PE20080715A1 (es) 2008-07-25
US20100234290A1 (en) 2010-09-16
IL195156A (en) 2014-07-31
NZ572708A (en) 2011-11-25
US20140235538A1 (en) 2014-08-21
KR20090027197A (ko) 2009-03-16
RU2008151511A (ru) 2010-07-20
DK2032155T3 (en) 2015-03-02
JO2968B1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
GT200800273A (es) Polipeptidos de factor de crecimiento de tipo insulina estabilizada
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
MX348622B (es) Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
CL2008003476A1 (es) Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
BR112014009418A2 (pt) macrociclos peptidomiméticos
PE20240686A1 (es) Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
CR20120339A (es) Análogo peptídico de oxintomodulina
WO2007104738A3 (en) Acylated single chain insulin
HK1142828A1 (en) Hydrolysable polymeric fmoc-linker
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
EA200702012A1 (ru) Пептиды механо-фактора роста и их применение
AU2010353685A8 (en) Novel glucagon like peptide analogs, composition, and method of use
DK2118136T3 (da) Konsensuspeptid
MX2010010177A (es) Fragmentos de beta timosina mejorada.
BR112014001844A2 (pt) gene induzindo o alongamento de raízes ou aumentando a biomassa, e uso do mesmo
ATE481414T1 (de) Von kollagen typ iv abgeleitetes cyclopeptid mit antikrebswirkung
EA200971092A1 (ru) Vegf-d мутанты и их применение
GB201018125D0 (en) Peptide
EA201390938A1 (ru) Зубной имплантат